Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, ...

6 September 2010, 2:33 pm

Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmina TMs Potential to Transform the Treatment of Retinal Disorders Leuven, Belgium a '-a ' ThromboGenics NV , a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second ...... Read More »

More Topics from "Buzz"

• Recipe for Water? Just Add Starlight
• Maltese contribution to Berlaymont Summa Arts Collection
• No Waste Restaurants, Window Gardening, Urban Honey on Menu of Gouter Bruxelles, Sept 20-26
• Downtime: 'Video nasties' moral panic enjoys renaissance in Belgium
• IFW World
• ThromboGenics Presents Positive Pooled Results from the MIVITRUST...
• For District II Director: Joseph R. Peterson
• Hundreds of fans turn out to mourn singer
• Belgian King Picks Mediators in Bid to Restart Talks on Forming Government